福辛普利钠联合多沙唑嗪治疗对肾性高血压患者血压控制及相关生物活性因子的影响

doi:10.3969/j.issn.1000-8535.2024.09.016

摘要/Abstract

摘要： 目的探讨福辛普利钠与多沙唑嗪联合对肾性高血压的治疗效果,并分析治疗后患者血压控制情况及相关活性因子变化。方法前瞻性选取天津市北辰区北辰医院2020年10月—2023年10月收治的98例肾性高血压患者,以随机数字表法作为分组方式,分为观察组（n=49）与对照组（n=49）。对照组患者采取福辛普利钠治疗,观察组在对照组基础上增加多沙唑嗪治疗。对比两组的血压控制效果,治疗前后一氧化氮（NO）、内皮素（ET）、血管紧张素Ⅱ（AngⅡ）相关生物活性因子水平变化,肾功能变化,不良反应发生情况。结果观察组总有效率89.79%,高于对照组的73.47%（χ²=4.356,P=0.037）;治疗后两组AngⅡ、ET水平均降低,且观察组[（13.62±2.24）ng/mL、（68.62±6.66）ng/L]低于对照组[（16.25±4.32）ng/mL、（74.26±9.35）ng/L],对比差异有统计学意义（t₁=3.783,t₂=3.439,P<0.001）;NO水平升高,观察组[（54.26±3.42）μmol/L]高于对照组[（50.51±2.37）μmol/L],对比差异有统计学意义（t=6.309,P<0.001）;治疗后两组血肌酐（Scr）、尿素氮（BUN）、胱抑素C（CysC）水平均降低,且观察组[（404.36±92.12）μmoI/ L、（13.34±4.31）mmol / L、（2.19±0.24）mg / L]低于对照组[（443.49±80.19）μmoI / L、（15.07±4.23）mmol / L、（2.87±0.38）mg / L],对比有统计学意义（t₁=2.243,P₁=0.027;t₂=2.005,P₂=0.048;t₃=10.591,P₃<0.001）;两组不良反应发生率对比差异无统计学意义（10.20% vs 8.16%,P>0.05）。结论对肾性高血压患者,采取福辛普利钠与多沙唑嗪联合治疗可提升其血压控制效果,改善血管内皮功能,降低血管紧张素Ⅱ表达水平,改善肾功能,且不增加不良反应。

关键词: 福辛普利钠, 肾性高血压, 多沙唑嗪, 舒张压, 收缩压, 生物活性因子

Abstract: Objective To explore the therapeutic effect of the combination of fosinopril sodium and doxazosin on renal hypertension,and to analyze the blood pressure control and changes in related active factors in patients after treatment．Methods A prospective study was conducted on 98 patients with renal hypertension admitted to Beichen Hospital from October 2020 to October 2023．Random number table method was used as the grouping method,and they were divided into an observation group（n=49）and a control group（n=49）．The control group patients were treated with fosinopril sodium,while the observation group was treated with doxazosin additionally．The blood pressure control effect,changes in levels of NO,ET,Ang II related bioactive factors,renal function changes before and after treatment,and their adverse reactions were compared．Results The total response rate in the observation group was 89.79%,which was higher than 73.47% in the control group（χ²=4.356,P=0.037）．Ang Ⅱ and ET levels in both groups decreased after treatment,the observation group[（13.62±2.24）ng/mL,（68.62±6.66）ng/L] was lower than the control group[（16.25±4.32）ng/mL,（74.26±9.35）ng/L],the difference was statistically significant（t₁=3.783,t₂=3.439,P<0.001）．Elevated NO levels in the observation group[（54.26±3.42）μmol/L] was higher than the control group[（50.51±2.37）μmol/L],the difference was statistically significant（t=6.309,P<0.001）．Blood Scr,BUN,and CysC levels were decreased in both treatment groups,and those in observation group[（404.36±92.12）μmoI/L,（13.34±4.31）mmol/L,（2.19±0.24）mg/L] were lower than the control group[（443.49±80.19）μmoI/L,（15.07±4.23）mmol/L,（2.87±0.38）mg/L],the differences were statistically significant（t₁=2.243,P₁=0.027;t₂=2.005,P₂=0.048;t₃=10.591,P₃<0.001;P<0.05）．There was no difference in the incidence of adverse effects between the two groups（10.20% vs 8.16%,P>0.05）．Conclusions The combination treatment of fosinopril sodium and doxazosin can improve the blood pressure control effect,improve endothelial function,reduce the expression level of angiotensin II,and improve renal function in patients with renal hypertension,with high safety．

Key words: fosinopril sodium, renal hypertension, dosazosin, diastolic blood pressure, systolic blood pressure, bioactive factor

丁会强, 李娜, 陈绍亮, 运学娇, 王萍. 福辛普利钠联合多沙唑嗪治疗对肾性高血压患者血压控制及相关生物活性因子的影响[J]. 广州医药, 2024, 55(9): 1060-1065.

DING Huiqiang, LI Na, CHEN Shaoliang, YUN Xuejiao, WANG Ping. Effects of fosinopril sodium combined with doxazosin on blood pressure control and related bioactive factors in patients with renal hypertension[J]. Guangzhou Medical Journal, 2024, 55(9): 1060-1065.

参考文献

[1] SARAFIDIS P A,THEODORAKOPOULOU M,ORTIZ A,et al.Atherosclerotic renovascular disease:A clinical practice document by the European Renal Best Practice(ERBP)board of the European Renal Association(ERA)and the Working Group Hypertension and the Kidney of the European Society of Hypertension(ESH)[J].Nephrol Dial Transplant,2023,38(12):2835-2850.
[2] SILVERWATCH J,MARTI KE,PHAN MT,et al.Renal denervation for uncontrolled and resistant hypertension:Systematic review and network Meta-Analysis of randomized trials[J].J Clin Med,2021,10(4):782.
[3] STAVROPOULOS K,PATOULIAS D,IMPRIALOS K,et al.Efficacy and safety of renal denervation for the management of arterial hypertension:A systematic review and meta-analysis of randomized,sham-controlled,catheter-based trials[J].J Clin Hypertens(Greenwich),2020,22(4):572-584.
[4] 刘晓云. 福辛普利钠联合松龄血脉康胶囊治疗原发性高血压的研究[J].航空航天医学杂志,2022,33(10):1215-1217.
[5] 胡渊,李斌.多沙唑嗪联合盐酸屈他维林治疗输尿管下段结石的效果[J].中国医药导报,2022,19(6):81-84.
[6] 刘涛,谢晨,王新强.多沙唑嗪联合替米沙坦预处理维持嗜铬细胞瘤切除术中循环稳定的效果[J].江苏医药,2022,48(10):1032-1036.
[7] 中国医药教育协会心血管内科专业委员会,中国医师协会高血压专业委员会,中华医学会心血管病学分会高血压学组.中国继发性高血压临床筛查多学科专家共识(2023)[J].心脑血管病防治,2023,23(1):1-24.
[8] AHMAD Y,FRANCIS D P,BHATT D L,et al.Renal denervation for hypertension:A systematic review and meta-analysis of randomized,blinded,placebo-controlled trials[J].JACC Cardiovasc Interv,2021,14(23):2614-2624.
[9] OGOYAMA Y,TADA K,ABE M,et al.Effects of renal denervation on blood pressures in patients with hypertension:A systematic review and meta-analysis of randomized sham-controlled trials[J].Hypertens Res,2022,45(2):210-220.
[10] LI L,XIONG YL,TU B,et al.Effect of renal denervation for patients with isolated systolic hypertension:A systematic review and meta-analysis[J].J Geriatr Cardiol,2023,20(2):121-129.
[11] AHMED M,NUDY M,BUSSA R,et al.A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension[J].Eur J Intern Med,2023(113):83-90.
[12] 孟红社. 醛固酮受体拮抗剂联合福辛普利钠片治疗充血性心力衰竭患者的临床疗效[J].慢性病学杂志,2022,23(12):1914-1916.
[13] 何同林,何兰,刘俊,等.高通量透析模式对改善维持性血液透析患者β2微球蛋白清除率及高血压的影响[J].广州医药,2021,52(5):35-39.
[14] 张琪,朱顺和,卜军.不同降压药物联合治疗高血压急症合并多器官损害1例报道[J].中西医结合心脑血管病杂志,2023,21(19):3655-3657.
[15] 钟葆文,姚史武,林毅锋.甲磺酸多沙唑嗪在输尿管镜手术治疗输尿管上段结石围术期中的应用[J].临床医学工程,2022,29(4):441-442.
[16] 钟晓,宋紫光,高萍萍,等.多沙唑嗪通过刺激半乳糖凝集素-3的表达促进心肌纤维化的研究[J].中国心血管病研究,2022,17(12):1074-1078.
[17] 郑丽华,钱一菁,卞艳芳,等.福辛普利钠联合多沙唑嗪对肾性高血压治疗患者血压控制及相关生物活性因子的影响[J].心脑血管病防治,2023,23(9):58-61.
[18] SYED M,OSMAN M,ALHAMOUD H,et al.The state of renal sympathetic denervation for the management of patients with hypertension:A systematic review and meta-analysis[J].Catheter Cardiovasc Interv,2021,97(4):E438-E445.
[19] 应葛霏,章茜茜.不同程度妊娠期高血压疾病患者血清ET-1、NO、CysC水平及肾功能指标变化[J].中国计划生育学杂志,2022,30(9):2107-2110.
[20] 孔琪,王慧,倪凤云.基于自噬-NLRP3炎症小体途径探究牛蒡子苷元对妊娠期高血压病大鼠血管内皮损伤的作用[J].中国中药杂志,2023,48(11):3022-3031.
[21] 李昊楠,王静,郑晶晶,等.血清ET-1、NO、GSH-Px水平在硬膜外阻滞麻醉胆道手术患者中水平变化及与胆心反射发生关系探讨[J].中国实验诊断学,2022,26(4):526-529.
[22] 刘孟楠,杨廷富,罗钢,等.NLRP3/IL-1β/TGF-β1信号轴在AngⅡ诱导高血压心肌纤维化小鼠中的作用研究[J].中国循证心血管医学杂志,2022,14(11):1320-1324.
[23] 周颖,谢先泽,蔡田恬,等.氯沙坦钾片联合百令胶囊对肾性高血压伴蛋白尿患者mALB、UACR、TGF-β的影响[J].中国中西医结合肾病杂志,2022,23(10):917-920.
[24] 张建丰,曹米林,梁琦,等.咖啡酸类衍生物hit1对肾血管性高血压大鼠的降压作用研究[J].中国现代应用药学,2023,40(5):626-631.
[25] RABBANI R,NOEL E,BOYLE S,et al.Role of antihypertensives in end-stage renal disease:A systematic review[J].Cureus,2022,14(7):e27058.
[26] BLAZEK O,BAKRIS G L.Novel therapies on the horizon of hypertension management[J].Am J Hypertens,2023,36(2):73-81.
[27] 李海燕,赵贵,刘佳.老年高血压病患者运用不同类型降压药物的临床药学特点研究[J].重庆医学,2022,51(S02):103-105.